Novo Nordisk A/S ’s (NVO) share price has entered into oversold territory with an RSI value of 21.9. The Zacks Consensus Estimate for Novo Nordisk for the full year period has improved 75 cents over the past two months to $1.90 per share. Currently, Novo Nordisk has a Zacks Rank #2 (Buy), suggesting that now might be a good time to get in on (NVO) after its recent drop.
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment